The promising labetuzumab-SN-38 conjugates developed showed selective therapeutic efficacy in human tumor models at nontoxic doses that were a fraction of the CPT-11 doses used.
No takes yet. Share an insight, caveat, or question.
Govindan et al. (2009) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: